First human-sized, living disc replacements derived from proprietary discogenic progenitor cells mark milestone in regenerative spine medicine
The International Society for the Advancement of Spine Surgery has recognized the peer-reviewed article reporting DiscGenics’ Phase I/II clinical trial results as one of the best and most influential articles published in the International Journal of Spine Surgery in 2024.
DiscGenics has gained acceptance from the U.S. FDA for the clinical protocols and Chemistry, Manufacturing, and Controls (CMC) clinical development plan for Phase III clinical program of its allogeneic, injectable disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease (DDD), allowing the study to proceed.
The International Journal of Spine Surgery publishes results from the combined Phase I/Phase II, first-in-human clinical study of an allogeneic disc progenitor cell therapy (IDCT or rebonuputemcel) for painful lumbar degenerative disc disease.
DiscGenics CEO and Chairman, Flagg Flanagan will present at Canaccord Genuity 2024 Musculoskeletal Conference taking place in San Francisco on Monday, February 12, 2024.
DiscGenics has announced a basic science Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs (VA) to assess the feasibility of using DiscGenics’ proprietary Discogenic Cells with the VA’s whole, tissue-engineered endplate-modified disc-like angle ply structure (eDAPS).
